Henry Schein vs TG Therapeutics
Henry Schein (HSIC), health care, and TG Therapeutics (TGTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
TG Therapeutics is worth $9.5B on the stock market and Henry Schein $9.2B: TG Therapeutics is valued at 3% more. Henry Schein trades at 22.7 times earnings and TG Therapeutics at 93.6; operating margins in their latest fiscal years were 4.95% and 20.0%. Over the past year Henry Schein's share price has moved +19.3% and TG Therapeutics's +101%.
Key facts
- Henry Schein market value
- $9.2B
- TG Therapeutics market value
- $9.5B
- Henry Schein P/E
- 22.7
- TG Therapeutics P/E
- 93.6
- Henry Schein revenue
- $13.2BFY to 2025-12-27
- TG Therapeutics revenue
- $616.3MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Henry Schein | TG Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-27 | 2025-12-31 |
| Size | ||
| Market cap | $9.2Blower | $9.5Bhigher |
| Revenue | $13.2Bhigher | $616.3Mlower |
| Earnings | $398Mlower | $447.2Mhigher |
| Employees | 25,000higher | 399lower |
| Total assets | $11.2Bhigher | $1.1Blower |
| Valuation | ||
| P/E | 22.7lower | 93.6higher |
| P/S | 0.7lower | 15.4higher |
| P/B | 2.9lower | 15.4higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 4.95%lower | 20.0%higher |
| Balance sheet | ||
| Net assets | $3.2Bhigher | $648Mlower |
| Total liabilities | $6.4Bhigher | $415.2Mlower |
| Total debt | $3.1Bhigher | $245.6Mlower |
| Cash on hand | $156Mhigher | $79.1Mlower |
| Price change | ||
| Today | -2.38%lower | -0.08%higher |
| 1 year | +19.3%lower | +101%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Henry Schein only (7)
- Andrew Wellington1.7%
- David Einhorn1.5%
- Pat English1.1%
- Mario Gabelli0.3%
- Richard Pzena0.2%
- Ken Griffin0.1%
- Mason Hawkins0.1%
TG Therapeutics only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio. Who owns HSIC
More on Henry Schein
Further comparisons
Henry Schein against its closest peers
TG Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Henry Schein or TG Therapeutics?
By market value, TG Therapeutics is the larger: $9.5B against $9.2B for Henry Schein. By revenue in its latest fiscal year, Henry Schein is the larger: $13.2B against $616.3M for TG Therapeutics.
Which has the higher P/E ratio?
TG Therapeutics: 93.6, against 22.7 for Henry Schein. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
TG Therapeutics: 20.0%, against 4.95% for Henry Schein. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Henry Schein: $3.1B, against $245.6M for TG Therapeutics. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Henry Schein and TG Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 7 hold Henry Schein and 0 hold TG Therapeutics.
Cite this page
Funkfolio, “Henry Schein vs TG Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/hsic-vs-tgtx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.